Hammoud Fatima, Ismail Ali, Zaher Reem, El Majzoub Rania, Abou-Abbas Linda
Faculty of Medical Sciences, Neuroscience Research Center, Lebanese University, Beirut, Lebanon.
Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Parkinsons Dis. 2025 Aug 18;2025:1319419. doi: 10.1155/padi/1319419. eCollection 2025.
Research into alternative treatments for Parkinson's disease (PD) is gaining increasing attention. (), a plant traditionally used in Ayurvedic medicine, contains a significant amount of L-dopa (4%-6%), the primary active component of conventional levodopa (LD) therapy-the gold standard treatment for PD. is also recognized for its anti-inflammatory, antioxidant, antiapoptotic, and antiparkinsonian properties, which collectively suggest therapeutic benefits for individuals with PD. This systematic review aims to investigate the efficacy and safety of in managing symptoms of PD. A comprehensive search was conducted in PubMed, Embase, and Web of Science for clinical trials published up to February 2024. Studies comparing to LD were included. Quality assessment was performed, and findings were synthesized narratively. Out of 466 articles identified, 5 clinical trials involving a total of 108 participants (mean age: 60 years) were included. Quality assessment rated one study as high quality, one as having some concerns, and three as low quality. Despite heterogeneity in interventions, the findings consistently showed improvements in PD symptoms and therapy-related complications. Treatment with was associated with a shorter time to reach the "on" disease stage, prolonged duration of this stage, and fewer adverse events, with no dyskinesia reported. shows promise in improving motor symptoms and reducing therapy complications in PD patients. However, current clinical evidence is limited, and further high-quality trials are needed to confirm its efficacy and safety.
对帕金森病（PD）替代疗法的研究正日益受到关注。（此处原文缺失具体植物名称），一种传统上用于阿育吠陀医学的植物，含有大量左旋多巴（4%-6%），这是传统左旋多巴（LD）疗法的主要活性成分——PD的金标准治疗方法。（该植物）还因其抗炎、抗氧化、抗凋亡和抗帕金森病特性而受到认可，这些特性共同表明对PD患者具有治疗益处。本系统评价旨在研究（该植物）在管理PD症状方面的疗效和安全性。在PubMed、Embase和Web of Science中进行了全面检索，以查找截至2024年2月发表的临床试验。纳入了比较（该植物）与LD的研究。进行了质量评估，并对研究结果进行了叙述性综合分析。在识别出的466篇文章中，纳入了5项临床试验，共涉及108名参与者（平均年龄：60岁）。质量评估将一项研究评为高质量，一项研究存在一些问题，三项研究评为低质量。尽管（该植物）干预措施存在异质性，但研究结果一致显示PD症状和治疗相关并发症有所改善。使用（该植物）治疗与达到“开”期疾病阶段的时间缩短、该阶段持续时间延长以及不良事件减少相关，且未报告有运动障碍。（该植物）在改善PD患者运动症状和减少治疗并发症方面显示出前景。然而，目前的临床证据有限，需要进一步的高质量试验来证实其疗效和安全性。
